Clinical and Molecular Response of STI571 in Patients with Advanced Chronic Myelogenous Leukemia / 대한혈액학회지
Korean Journal of Hematology
;
: 9-16, 2002.
Artigo
em Coreano
| WPRIM
| ID: wpr-720365
ABSTRACT
BACKGROUND:
STI571, a potent and specific inhibitor of the BCR-ABL tyrosine kinase, causes arrest of growth or apoptosis in leukemic cells that express BCR-ABL. We evaluated the therapeutic effects and clinical events after the STI571 treatment in advanced chronic myelogenous leukemia (CML).METHODS:
STI571 was administered orally to 24 patients with CML in accelerated phase (AP) (N=17) or blast crisis (BC) (N=7) with a daily dose of 600mg. Adverse events were observed, and hemotologic, cytogenetic, and molecular responses were evaluated on 1 month of STI571 treatment.RESULTS:
Hematologic responses were observed in 20 of 24 patients with higher complete hematologic responses in AP (35.3%) compared to BC (14.3%). Partial cytogenetic responses were observed in 2 cases. Fluorescence in situ hybridization showed significant decrease in the percentage of BCR-ABL positive cells, but all still remained above the upper limit of normal range at the time of analysis. No significant changes were observed in BCR-ABL transcripts after treatment by reverse transcription polymerase chain reaction (PCR) and real-time quantitative PCR. Non- hematologic adverse events after STI571 treatment were minimal, whilst hematologic ones were significant with higher frequency in BC rather than AP.CONCLUSION:
STI571 induced rapid and significant hematologic responses in patients with advanced CML and adverse events were tolerable. The fact that no responses were achieved in some of these advanced cases underlies the importance of earlier treatment with STI571 to prolong the survival.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Valores de Referência
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Crise Blástica
/
Reação em Cadeia da Polimerase
/
Proteínas de Fusão bcr-abl
/
Hibridização In Situ
/
Apoptose
/
Citogenética
/
Transcrição Reversa
/
Fluorescência
Limite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Hematology
Ano de publicação:
2002
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS